Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

High vitamin D levels may prevent death in patients with CKD

16 Jul 2017

Higher serum levels of 25-hydroxyvitamin D (25[OH]D) may likely reduce the risk of all-cause mortality in patients with chronic kidney disease (CKD), reports a study. However, evidence is inconclusive with regard to serum levels of >35 ng/mL.

To investigate the association between different levels of serum 25(OH)D and risk of all-cause mortality, researchers systematically searched Medline and Embase from inception to November 2016 for studies that reported risk estimates of all-cause mortality for three or more categories of serum 25(OH)D in patients with CKD. Also included were those that reported results as continuous.

A total of 1,281 studies were identified, of which 13 prospective cohort studies, two retrospective cohort studies and one nested case-control study were included. These involved 17,053 patients and 7,517 incident deaths.

The authors used a random-effects models to combine reported risk estimates. Summary risk estimates of all-cause mortality were 1.63 (95 percent CI, 1.32 to 1.94) for severe vitamin D deficiency (<10 ng/ml), 1.22 (1.09 to 1.35) for mild deficiency (10 to 20 ng/mL) and 1.12 (1.06 to 1.18) for insufficiency (20 to 30 ng/mL). These findings were more evident in dialysis-dependent patients.

A 10-ng/mL increase in serum 25(OH)D was associated with a 21-percent decrease in the risk of overall mortality (relative risk, 0.79; 0.70 to 0.87). There was also a lower risk of all-cause mortality at a serum 25(OH)D of 25 to 30 ng/mL. One of the sources of variation between studies was dialysis treatment.

Patients with CKD have a high prevalence of vitamin D deficiency, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.